The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.

Multi-modal imaging capsule for image-guided proton beam therapy, consisting of a biocompatible polymer layer, .sup.18O-enriched water, and a contrast agent. The biocompatible capsule may be inserted near or inside a tumor under the guidance of X-ray, magnetic resonance, or ultrasonography imaging. Upon proton beam irradiation, the capsule emits positrons, allowing the tumor to be imaged and tracked by a PET detector.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and/or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

Disclosed herein is an injectable anticancer composition for local administration, which contains a suspension of quinine hydrochloride. The anticancer composition for local administration according to the present invention shows an IC.sub.50 value against MKN-45 cells, which is about 10 times lower than Paclitaxel, as determined by an MTT assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect. The anticancer composition can be administered as a safe anticancer agent in clinical applications, and also shows an anticancer effect by inducing the necrosis and detachment of solid cancer cells. Particularly, the anticancer composition has an anticancer mechanism by which the composition acts locally in a tumor tissue administered with the composition and shows a rapid antitumor effect (1-2 weeks after administration).

The present invention provides compositions, and related kits and methods, for formation of hydrogels. The compositions comprise one or more chemically crosslinkable agents dissolved in an aqueous solution to form a precursor solution. The chemically crosslinkable agents useful in the present invention are selected from polymers modified with a molecule selected from acrylate, maleimide, vinylsulfone, N-hydroxysuccinimide, aldehyde, ketone, carbodiimide, carbonate, iodoacetyl, mercaptonicotinamide, quinone, thiol, amine, and combinations thereof. The precursor solution is characterized as being in an aqueous form at a non-physiologic physical-chemical condition and undergoing gelation when in contact with another fluid or body at a physiologic physical-chemical condition.

This document provides materials and methods for permanent arterial embolization and/or enhanced vascular healing. For example, materials and methods for using bioactive tissue derived nanocomposite hydrogels to enhance vascular healing are provided.

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.